Educational Information Only
The following is a summary of published preclinical research and is provided for informational and educational purposes only. No information in this article constitutes a claim that any product sold by Ovrform treats, cures, prevents, or mitigates any disease or medical condition. All referenced studies were conducted in non-human models unless otherwise specified. This content does not constitute medical advice and should not be relied upon as a substitute for consultation with a qualified healthcare professional. Ovrform does not endorse or recommend the use of any product for human or veterinary purposes.
This article is published for educational and informational purposes only. It is not medical advice, not a diagnosis or treatment recommendation, and not guidance for use of any kind. Independent third-party research described here does not represent claims about Ovrform products, and no outcome, benefit, or effect should be inferred for any Ovrform product. Where published study methods are reported, amounts, routes, and schedules are described only to characterize that research accurately — they are not instructions, protocols, or recommendations, and Ovrform does not provide dosing or administration guidance. All Ovrform products are supplied for laboratory research use only and are not for human or animal consumption or use.
Structural Reference · Incretin Analogs
Semaglutide vs Tirzepatide vs Retatrutide
A structural and chemical comparison across receptor classification, peptide backbone, chain length, lipidation chemistry, molecular profile, and analytical research format. Limited to structural and analytical characteristics only, with no dosing, administration, or physiological content.
Mono-agonist
Semaglutide
31 RESIDUES
GLP-1 receptor agonist. Shortest backbone in the group and the most receptor-selective of the three.
Dual agonist
Tirzepatide
39 RESIDUES
GIP and GLP-1 receptor agonist. Longer backbone with a broader receptor-target profile.
Tri-agonist
Retatrutide
39 RESIDUES
GIP, GLP-1, and glucagon receptor agonist. Broadest receptor-targeting architecture here.
Neutral, research-use-only reference articles on peptide classification, structure, and analytical documentation. These articles summarize independently published third-party literature. The studies and their authors are not affiliated with, sponsored by, or endorsed by Ovrform, and nothing here describes or implies any use of Ovrform products.
Key Takeaways
Three lipidated peptide analogs, distinguished by receptor breadth
Semaglutide, tirzepatide, and retatrutide are synthetic, lipidated peptide analogs associated with incretin and metabolic research. Their primary structural distinction is the number of receptor systems each compound is designed to engage.
- Semaglutide is a GLP-1 receptor mono-agonist with a 31-residue peptide chain.
- Tirzepatide is a GIP and GLP-1 receptor dual agonist with a 39-residue peptide chain.
- Retatrutide is a GIP, GLP-1, and glucagon receptor tri-agonist with a 39-residue peptide chain.
All three share a related glucagon-superfamily peptide architecture, but they differ in receptor-target breadth, amino acid sequence, lipid conjugation, and overall molecular profile. This reference does not address dosing, administration, clinical outcomes, or physiological effects. The compounds discussed are intended for research-use-only contexts.
01 · At a Glance
Comparison table
| Characteristic | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor classification | GLP-1 mono-agonist | GIP and GLP-1 dual agonist | GIP, GLP-1, and glucagon tri-agonist |
| Peptide family | Glucagon-superfamily analog | Glucagon-superfamily analog | Glucagon-superfamily analog |
| Peptide structure | Linear synthetic peptide | Linear synthetic peptide | Linear synthetic peptide |
| Reported chain length | 31 amino acid residues | 39 amino acid residues | 39 amino acid residues |
| Lipidation | Present | Present | Present |
| General research format | Lyophilized peptide powder | Lyophilized peptide powder | Lyophilized peptide powder |
| Common identity methods | HPLC and mass spectrometry | HPLC and mass spectrometry | HPLC and mass spectrometry |
02 · Primary Distinction
What is the main difference between the three?
The main difference is receptor selectivity. Semaglutide is designed to act as a single-receptor agonist at the glucagon-like peptide-1 receptor, commonly called the GLP-1 receptor.
Tirzepatide expands this architecture by targeting two receptor systems: the glucose-dependent insulinotropic polypeptide receptor, commonly called the GIP receptor, and the GLP-1 receptor. Retatrutide extends the same design concept to three receptor systems, classified as an agonist at the GIP, GLP-1, and glucagon receptors.
01
Semaglutide
Single-receptor targeting
02
Tirzepatide
Dual-receptor targeting
03
Retatrutide
Triple-receptor targeting
This progression from mono-agonism to dual agonism and tri-agonism is the central basis for comparing the three peptides.
03 · Receptor Classification
Receptor classification by compound
Semaglutide: GLP-1 mono-agonist
Semaglutide is a synthetic peptide analog classified as a GLP-1 receptor agonist. It is the most receptor-selective compound in this comparison because it is directed primarily at one receptor class. Its structure is based on the broader glucagon and secretin peptide superfamily, with sequence modifications and lipidation incorporated into the final molecule.
Tirzepatide: GIP and GLP-1 dual agonist
Tirzepatide is a synthetic dual-receptor peptide agonist engineered to interact with both the GIP and GLP-1 receptors. Compared with semaglutide, it has a broader receptor-target profile and a longer peptide backbone. Its dual-agonist classification is the primary feature that distinguishes it from a GLP-1 selective analog.
Retatrutide: GIP, GLP-1, and glucagon tri-agonist
Retatrutide is a synthetic tri-agonist designed to engage the GIP, GLP-1, and glucagon receptors. It represents the broadest receptor-targeting architecture among the three peptides. Structurally, it uses a longer peptide backbone and engineered residue pattern intended to support activity across three related receptor classes.
04 · Peptide Class
Peptide class and backbone structure
Semaglutide, tirzepatide, and retatrutide are linear synthetic peptides. They are not recombinant proteins. Each compound is modeled on peptide hormones within the glucagon and secretin superfamily. Members of this peptide family share related backbone features but can be modified to alter receptor selectivity, chemical stability, and molecular behavior in experimental systems.
Chain length comparison
Semaglutide has the shortest peptide chain in the group, with 31 amino acid residues. Tirzepatide and retatrutide each use longer 39-residue peptide backbones.
The difference in chain length contributes to variations in molecular weight, amino acid composition, secondary structure, and receptor interaction. However, chain length alone does not determine receptor selectivity — the identity and position of individual amino acid substitutions are also important.
05 · Conjugate Chemistry
Lipidation and conjugate chemistry
A major structural similarity among the three compounds is lipidation — the covalent attachment of a fatty-acid-derived component to the peptide chain. In this class of compounds, the lipid component is generally connected to a lysine side chain through a spacer or linker system.
Linker architecture may include
- A gamma-glutamate unit
- Short hydrophilic spacer groups
- A fatty diacid or related lipid moiety
- A lysine residue serving as the conjugation site
Although all three peptides use lipidation, their exact fatty-acid components, linker arrangements, and conjugation chemistry are not identical. In laboratory research, lipidation is commonly studied for its relationship to reversible albumin binding and altered peptide behavior in biological matrices. It also distinguishes these synthetic analogs from shorter, non-lipidated native incretin peptides.
06 · Sequence Engineering
Amino acid engineering
These peptides contain engineered amino acid substitutions that differentiate them from naturally occurring peptide hormones. One modification associated with this peptide class is the use of alpha- aminoisobutyric acid, commonly abbreviated as Aib. Aib is a non-proteinogenic amino acid, meaning it is not one of the standard genetically encoded amino acids used in natural protein synthesis.
Aib substitutions may be placed at positions that are susceptible to enzymatic cleavage. In analytical and biochemical research, these substitutions are associated with increased resistance to degradation by dipeptidyl peptidase-4, commonly called DPP-4. The precise sequence and location of engineered residues vary among the three compounds, and these sequence-level differences contribute to each peptide’s receptor classification and molecular properties.
07 · Molecular Profile
Molecular profile comparison
The molecular profiles differ because of three main factors: peptide chain length, amino acid sequence and residue substitutions, and lipid and linker composition.
Semaglutide is generally the lightest of the three compounds because it has the shortest peptide backbone. Tirzepatide and retatrutide are larger 39-residue peptides; their exact molecular weights differ because they do not share identical amino acid sequences or conjugate structures.
Why lot-specific documentation matters
Exact analytical constants should be confirmed using documentation associated with the individual research lot. Relevant records may include:
- Certificate of analysis
- Chromatographic purity results
- Observed molecular mass
- Counterion or salt information
- Mass spectrometry data
- Molecular formula
- Monoisotopic mass
- Water or solvent content
08 · Format & Analysis
Physical format and analytical identification
All three peptides are commonly supplied for laboratory research as lyophilized peptide powders. Lyophilization, also called freeze-drying, removes water under controlled conditions to produce a dry peptide material. The resulting product is often described as a white or off-white powder, although appearance alone cannot establish identity or purity.
Reversed-phase high-performance liquid chromatography
RP-HPLC is commonly used to evaluate peptide purity and detect related substances. An HPLC purity percentage reflects chromatographic composition under the specified test conditions; it should not be interpreted as a complete confirmation of chemical identity by itself.
Mass spectrometry
Mass spectrometry is used to compare the observed molecular mass with the expected mass of the target peptide. Depending on the analytical method, a report may include a neutral molecular mass, mass-to-charge values, isotope patterns, or deconvoluted mass data.
Additional characterization
Amino acid analysis
Peptide mapping
Water content
Residual solvents
Counterion analysis
Endotoxin testing
Bioburden / sterility
NMR analysis
The appropriate testing panel depends on the research application and the material specification.
09 · Shared vs Distinct
Shared features and key differences
Shared structural features
- They are synthetic peptide analogs.
- They belong to the glucagon-superfamily design space.
- They use linear peptide backbones.
- They contain engineered amino acid substitutions.
- They incorporate lipid conjugation.
- They are commonly evaluated using HPLC and mass spectrometry.
- They are frequently supplied in lyophilized research formats.
Key structural differences
Receptor-target breadth
Semaglutide targets one receptor class, tirzepatide targets two, and retatrutide targets three.
Peptide chain length
Semaglutide contains 31 residues. Tirzepatide and retatrutide contain 39 residues.
Amino acid sequence
Each compound has a distinct engineered sequence, influencing receptor selectivity and molecular behavior.
Lipid conjugate
All three are lipidated, but the composition and arrangement of the lipid, linker, and conjugation site differ.
Molecular mass
Semaglutide is generally lighter due to its shorter backbone. Exact masses must be confirmed from analytical records.
10 · FAQ
Frequently asked questions
Are semaglutide, tirzepatide, and retatrutide the same type of peptide?
They belong to the same broad structural family but are not the same peptide. Each has a distinct amino acid sequence, receptor profile, and conjugate chemistry.
What is the difference between a mono-agonist, dual agonist, and tri-agonist?
A mono-agonist is designed to engage one receptor class, a dual agonist targets two, and a tri-agonist targets three. Here, semaglutide is a mono-agonist, tirzepatide is a dual agonist, and retatrutide is a tri-agonist.
Which receptors are associated with semaglutide?
Semaglutide is classified as a GLP-1 receptor agonist.
Which receptors are associated with tirzepatide?
Tirzepatide is classified as a dual agonist at the GIP and GLP-1 receptors.
Which receptors are associated with retatrutide?
Retatrutide is classified as a tri-agonist at the GIP, GLP-1, and glucagon receptors.
How many amino acids are in semaglutide?
Semaglutide has a 31-residue peptide chain.
How many amino acids are in tirzepatide and retatrutide?
Tirzepatide and retatrutide each have 39-residue peptide backbones.
Are all three peptides lipidated?
Yes. All three compounds incorporate a lipid component attached to the peptide through an engineered conjugation and linker arrangement.
Are these compounds recombinant proteins?
No. They are generally described as chemically synthesized, linear peptide analogs rather than recombinant proteins.
How are research peptide identity and purity confirmed?
Identity and purity are commonly evaluated using mass spectrometry and reversed-phase HPLC. Additional testing may be required depending on the research specification.
Can appearance confirm peptide identity?
No. A white or off-white lyophilized powder is not visually specific. Identity must be supported by analytical testing and lot-specific documentation.
Conclusion
A synthetic incretin-peptide design continuum
Semaglutide uses a 31-residue backbone and GLP-1 receptor mono-agonist architecture. Tirzepatide uses a longer 39-residue backbone and expands receptor targeting to both GIP and GLP-1. Retatrutide also uses a 39-residue backbone but extends the design to GIP, GLP-1, and glucagon receptor agonism.
Their shared characteristics include synthetic peptide construction, engineered amino acid substitutions, lipid conjugation, lyophilized research formats, and analytical characterization by chromatography and mass spectrometry. Their defining differences are receptor-target breadth, peptide sequence, chain length, molecular mass, and lipid-linker chemistry. Exact molecular constants and purity specifications should always be verified against the certificate of analysis and analytical documentation for the specific research lot.